It was known that high BChE levels are interconnected with the distinctive neuropathologic characteristic of Alzheimer’s disease (AD) and that both enzymes BChE and AChE are pharmacologically appropriate targets in neurodegenerative disorders. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.